Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783662 | 0.77 | MAPT (0.45) | MAPTRAB9AMT-CO2POLBGAA | |
| SCHEMBL11702566 | 0.77 | RAB9A (0.50) | MAPTRAB9AMT-CO2POLBGAA | |
| SCHEMBL18993119 | 0.75 | GAA (0.47) | MAPTRAB9AMT-CO2POLBGAA | |
| SCHEMBL20016242 | 0.74 | RAB9A (0.55) | MAPTRAB9APOLBGAASMN1; SMN2 | |
| SCHEMBL1692082 | 0.74 | — | — | |
| SCHEMBL11708876 | 0.73 | MAPT (0.47) | MAPTRAB9AMT-CO2POLBGAA | |
| SCHEMBL3779701 | 0.73 | RAB9A (0.41) | MAPTRAB9AGAASMN1; SMN2MEN1 | |
| SCHEMBL3788427 | 0.73 | MAPT (0.41) | MAPTRAB9AMT-CO2POLBGAA | |
| SCHEMBL3791776 | 0.72 | CETP (0.43) | POLBGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11704600 | 0.72 | MAPT (0.46) | MAPTRAB9AMT-CO2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| EP-3738956-A1 | CXCR2 ANTAGONIST | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | MAPT 4819/4885RAB9A 2084/4885MT-CO2 4501/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | MAPT 4819/4885RAB9A 2084/4885MT-CO2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.